IOL Chemicals Peer Comparison

NSE: IOLCP | BSE: 524164

₹199.95

₹3.52 (1.79%)

As on 04-Sep-2026 15:59IST

Market cap

₹5,872 Cr

Revenue (TTM)

₹2,524 Cr

P/E Ratio

34.9

P/B Ratio

3.2

Div. Yield

0.1 %

Edit

	IOL Chemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Market cap (₹ Cr)	5,872	36,584	29,051	16,782	15,009
Revenue (₹ Cr)	2,524	9,683	2,372	2,590	676
Net Profit (₹ Cr)	168.11	1,018.97	497.77	603.02	183.60
Net Margin (%)	6.60	10.47	20.72	22.63	26.06
RoE (%)	9.94	21.30	28.49	19.61	22.72
Price to Earnings	34.93	36.17	58.36	27.83	82.18
Price-To-Book	3.15	6.99	14.37	4.82	16.25

Income Statement (₹ Cr)

	IOL Chemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Operating Revenue	2,523.63	9,683.45	2,371.81	2,590.40	675.61
Total Income	2,545.82	9,730.84	2,402.61	2,664.23	704.48
Total Expenditure	2,213.31	7,739.53	1,608.91	1,753.71	442.67
EBITDA	310.32	1,943.92	762.90	836.69	232.94
Depreciation	81.80	425.10	98.11	78.88	15.56
EBIT	228.52	1,518.82	664.79	757.81	217.38
Interest	13.96	148.45	26.33	5.43	7.96
Other Income	22.19	47.39	30.80	73.83	28.87
Exceptional Items	-11.21	-27.85	0.00	-25.66	0.00
Profit before Tax	225.54	1,389.91	669.26	800.55	238.30
Provision for Tax	57.43	370.94	171.48	197.53	54.69
Profit after Tax	168.11	1,018.97	497.77	603.02	183.60

	IOL Chemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Shareholder's Funds	1,798.55	4,950.03	1,874.47	3,332.13	883.34
Minority Interest	0.00	-7.58	0.00	0.00	-0.97
Non-Current Liabilities	98.22	723.57	345.47	142.73	74.82
Current Liabilities	690.18	3,912.24	710.20	508.04	201.96
Total Liabilities	2,630.26	9,514.48	2,930.14	4,157.10	1,174.38

	IOL Chemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Non-Current Assets	1,291.11	3,392.16	1,290.62	1,321.38	477.92
Current Assets	1,227.63	5,612.10	1,483.13	2,649.36	623.97
Total Assets	2,630.26	9,514.48	2,930.14	4,157.10	1,174.38
Total Debt*	132.00	1,204.08	196.61	0.00	148.29
Net Current Assets	537.45	1,699.86	772.93	2,141.33	422.01
Contingent Liabilities	5.66	258.92	13.18	4.82	--

	IOL Chemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Cash From Operating Activities	214.32	943.55	346.68	565.41	69.55
Cash Flow from Investing Activities	-198.11	-1,193.06	-423.73	-570.15	-330.93
Cash from Financing Activities	-29.03	343.43	20.98	-64.34	247.29
Net Cash Inflow / Outflow	-12.82	93.92	-56.08	-69.08	-14.09

	IOL Chemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
ROCE (%)	10.65	25.25	27.50	24.61	28.50
ROE (%)	9.94	21.30	28.49	19.61	22.72
ROA (%)	6.77	11.42	19.48	16.31	31.25
EBIT Margin (%)	9.06	15.68	28.03	29.25	32.18
Net Margin (%)	6.60	10.47	20.72	22.63	26.06
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	IOL Chemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Revenue Growth (%)	18.56	18.36	78.33	7.93	23.56
EBIT Growth (%)	65.13	30.43	303.07	19.88	12.00
Net Profit Growth (%)	60.06	32.39	182.61	21.66	20.07
EPS Growth (%)	-33.09	36.68	277.72	25.42	50.65
Book Value Growth (%)	6.57	11.36	22.95	18.43	79.97

	IOL Chemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Price / Earnings	33.27	35.43	58.36	26.95	78.98
Price / Book Value	3.15	6.99	14.37	4.82	16.25
Dividend Yield (%)	0.10	0.19	0.15	0.37	0.11
EV/EBITDA	18.70	19.36	37.87	19.12	64.58
Market Cap (₹ Cr)	2,135.62	30,257.56	15,412.11	11,956.86	6,690.53

	IOL Chemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Debt to Equity	0.00	0.05	0.09	0.00	0.04
Short term debt to equity ratio	0.07	0.16	--	--	0.12
Current Ratio	1.78	1.43	2.09	5.21	3.09
Quick Ratio	1.24	0.82	1.37	3.85	2.02
Interest Coverage	17.16	10.36	26.41	148.49	30.94

	IOL Chemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Debtors to sales (%)	23.90	26.46	22.82	41.42	33.68
Asset Turnover	1.02	1.09	0.93	0.70	1.15
Receivable days	87.89	88.68	77.32	144.58	115.16
Inventory Days	57.58	84.11	80.83	96.67	96.15
Payable days	111.69	176.65	125.94	135.45	106.08
Cash Conversion Cycle	33.78	-3.86	32.22	105.80	105.23

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.